The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.
Has had ulcerative colitis (UC) (from onset of symptoms) for at least 3 months before Randomization
Has moderately to severely active UC
Has a weight ≥40 kg
Satisfies at least 1 of the criteria: Has had an inadequate response or loss of response to 1 or more protocol-specified treatments; protocol specified corticosteroid dependence; has been intolerant to 1 or more protocol-specified UC treatments
Has a diagnosis of Crohn's Disease (CD) or indeterminate colitis (inflammatory bowel disease (IBD)-undefined) or other types of colitis or enteritis that may confound efficacy assessment
Has a current diagnosis of fulminant colitis and/or toxic megacolon
Has UC limited to the rectum
Has a current or impending need for colostomy or ileostomy
Merck Sharp & Dohme LLC
Lead sponsor